Advertisement

Surgical Case Reports

, 5:11 | Cite as

Nontuberculous mycobacterial infection after lung transplantation: a report of four cases

  • Naoko OseEmail author
  • Masato Minami
  • Soichiro Funaki
  • Takashi Kanou
  • Ryu Kanzaki
  • Yasushi Shintani
Open Access
Case Report

Abstract

Background

Nontuberculous mycobacterium (NTM) infection in a patient in an immunosuppressed state caused by increased use of immunosuppressive or biological agents is a serious clinical problem. Mycobacterium avium complex is the most common involved pathogen, followed by Mycobacterium abscessus (MABSC), while Mycobacterium kansasii is not a major concern. The rate of infection rate in lung transplant recipients is reported to range from 1.5–22.4%.

Case presentation

We report here four cases of NTM pulmonary infection and disease among 63 patients who underwent lung or heart-lung transplantation at our hospital. Those four occurred following living-donor transplantation in two patients, one with pulmonary arterial hypertension and one with bronchiectasia, and deceased donor lung transplantation in two patients, lymphangioleiomyomatosis and interstitial pneumonia, respectively. NTM was not detected in any of the patients prior to transplantation. The involved pathogens were Mycobacterium gordonae in one, MAC in one, and MABSC in two of these patients, which were isolated from broncho-alveolar lavage (BAL) in two and sputum in two. The one case of MAC and two of MABSC were symptomatic with consolidation shown in chest CT images indicating possible pneumonia, while the one with M. gordonae had no symptoms and was detected by surveillance BAL. Onset time from detection of NTM was greater than 3 years in the three with MABSC and M. gordonae and less than 3 years in the one with MAC. Each patient required a decrease in immunosuppressive agents according to their condition, while antibiotics therapy was performed in the three who were symptomatic. Sputum culture findings became negative after several months and were maintained thereafter in all.

Conclusion

An NTM infection leading to pulmonary disease can occur at any time following lung transplantation. Treatment should be considered depending on the involved pathogens, individual status, and disease severity.

Keywords

Nontuberculous mycobacteriosis NTM Infection Lung Transplantation 

Abbreviations

AATD

α-1 antitrypsin deficiency

AMK

Amikacin

AZM

Azithromycin

BAL

Broncho-alveolar lavage

BE

Bronchiectasis

BL

Bilatetal lung

BOS

Bronchiolitis obliterans syndrome

C

Clarithromycin

CF

Cystic fibrosis

CHD

Congenital heart disease

Ci

Ciprofloxacin

COPD

Chronic obstructive pulmonary disease

CT

Computed tomography

CyA

Ciclosporin

E

Ethambutol

HL

Heart-lung

IPM

Imipenem

LAM

Lymphangioleiomyomatosis

LDLT

Living donor lung transplantation

M.

Mycobacterium

MABSC

Mycobacterium abscessus

MAC

Mycobacterium avium complex

MMF

Mycophenolate mofetil

NSIP

Nonspecific interstitial pneumonia

NTM

Nontuberculous mycobacteriosis

P

Pyridoxal phosphate hydrate

PAH

Pulmonary arterial hypertension

PSL

Prednisolone

R

Rifampicin

REC

Rifampicin, ethambutol, and clarithromycin

RFP

Rifampicin

Ri

Rifabutin

SL

Single lung

TAZ/PIPC

Tazobactam/piperacillin

Background

The number of patients with pulmonary nontuberculous mycobacterium (NTM) is increasing worldwide [1, 2], with NTM infection in patients in an immunosuppressed state caused by increased use of immunosuppressive or biological agents a serious clinical problem. Isolation of NTM organisms following lung transplantation is reported to occur in 1.5–22.4% [3, 4, 5, 6, 7, 8, 9, 10, 11] of those patients, some of whom suffer from pulmonary disease. The most common strain varies among regions and countries, which is an important factor because effective treatment methods differ depending on the causative pathogen. Furthermore, onset period and infection site in the native or transplanted lung are critical for effective treatment.

We report here four cases of NTM pulmonary infection in patients who underwent lung transplantation and were treated at our institution and also review previous reports with focus on onset time and NTM strain. Of 63 patients at our hospital who underwent lung transplantation between January 2000 and January 2018, including heart-lung and living-donor transplantation, four (6.3%) had NTM isolated from obtained specimens, while NTM was not detected in any prior to transplantation. Surveillance bronchoscopy examinations were performed four times the first year and then annually until 5 years after transplantation, according to our institutional protocol. After the fifth year, clinically indicated bronchoscopic examination is occasionally performed when rejection or respiratory infection suspects. In the present cases, clinical samples were obtained from sputum and bronchial lavage samples obtained with bronchoscopy. Mycobacterial cultures were performed using Ogawa medium or a Mycobacteria Growth Indicator Tube system. No Mycobacterium (M.) tuberculosis organisms were isolated in any of the present cases.

Case presentations

Case 1

An 11-year-old boy with pulmonary arterial hypertension underwent living-donor lung transplantation, with tacrolimus, mycophenolate mofetil (MMF), and prednisolone (PSL) given as immunosuppressive agents. At 76 months after transplantation, M. gordonae was isolated from a broncho-alveolar lavage (BAL) sample obtained during a surveillance examination. Contamination was suspected, because even though there were no symptoms, chest computed tomography (CT) showed a slight amount of consolidation in the left upper lesion (Fig. 1a). PSL as therapeutic and diagnostic treatment was decreased. Sputum culture findings were negative after 5 months, and chest CT images were clear. There was no further NTM detection during the following 15 years.
Fig. 1

ad. Chest computed tomography showing consolidation. a Case 1, slight consolidation in left upper lesion caused by M. gordonae. b Case 2, consolidation in left lower lesion caused by M. abscessus. c Case 3, consolidation in transplanted lung caused by M. abscessus. d Case 4, consolidation in native lung caused by M. intracellulare

Case 2

A 38-year-old female with bronchial ectasia underwent living-donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 82 months after transplantation, the patient developed a fever with purulent sputum and chest CT showed consolidation in the left lower lesion (Fig. 1b). M. abscessus complex (MABSC) was isolated from a BAL sample. Following administrations of tazobactam/piperacillin and azithromycin (AZM), as well as a decrease in ciclosporin from 120 to 50 mg for 1 month, the sputum cultures became negative. AZM administration and decreased ciclosporin were continued for 22 months, with no recurrence noted.

Case 3

A 39-year-old female with lymphangioleiomyomatosis underwent single deceased donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 58 months after transplantation, a fever developed and chest CT showed consolidation in the transplanted lung (Fig. 1c). MABSC was isolated in a cultured sputum sample. Following administrations of imipenem, amikacin, and AZM for 4 months, sputum culture findings became negative. Maintenance therapy with imipenem and amikacin was given once a week, along with daily AZM and a decrease in MMF, with no recurrence seen during the following 1-year period.

Case 4

A 41-year-old male with interstitial pneumonia underwent single deceased donor lung transplantation, with ciclosporin, MMF, and PSL given as immunosuppressive agents. At 12 months after transplantation, a fever developed and chest CT showed consolidation in the native lung (Fig. 1d), which was suspected to be pneumonia caused by general bacteria. Broad-spectrum antibiotic therapy was started, though was not effective. After a period of time, M. intracellulare was isolated from a cultured sputum sample. Thereafter, rifampicin (RFP), ethambutol, and clarithromycin (REC) treatment was administered for 3 months, after which sputum findings were negative. Rifampicin was continued at 800 mg, the standard level, while ciclosporin was adjusted according to trough level and finally administered at 550–600 mg, three times the normal dose, and PSL was gradually reduced. The patient died after 21 months because of respiratory failure due to chronic rejection, though sputum culture findings remained negative with REC treatment These cases are summarized in Table 1.
Table 1

Summary of 4 cases

Case No.

Age

Sex

Primary disease

Donar

Procedure

Period to onseta (Month)

Organism

Infection lung

Symptom

Diagnosis

Drug

Period to negative conversion (month)

Treatment period (month)

Reinfection

outcome

1

10

M

PAH

Living

Bilateral

Late (76)

M.gordonae

Transplanted

None

BAL

None

5

None

Alive

2

35

F

BE

Living

Bilateral

Late (82)

MABSC

Transplanted

Fever

Sputum

BAL

TAZ/PIPC+AZM

1

22

None

Alive

3

41

F

LAM

Cadaveric

Single

Late (58)

MABSC

Transplanted

Sputum

Sptum

AZM + IPM + AMK

4

12

None

Alive

4

39

M

NSIP

Cadaveric

Single

Early (12)

M.intracellurare

Native

Fever

Sptum

REC

3

21

None

Dead

AZM azithromycin, BAL broncho-alveolar lavage, BE bronchiectasis, CyA Cycrosporin, LAM lymphangioleiomyomatosis, M. Mycobacterium, MMF mycophenolate mofetil, NSIP nonspecific interstitial puemonia, PAH pulmonary arterial hypertension, PSL prednisolone, REC Rifampicin, ethambutol, and clarithromycin

aEarly onset considered to occur within 180 days, late onset from 180 days until 3 years, and very late onset after 3 years

Discussion

The number of patients worldwide with pulmonary NTM disease is increasing [1, 2]. An NTM infection is not contagious, whereas an MABSC infection can be acquired through transmission, potentially via fomites or aerosols [12]. Floto et al. reported that an NTM infection occurring in patients with cystic fibrosis can be problematic, as that can influence the indication for lung transplantation [13].

NTM infection following transplantation is a critical issue, because treatment is difficult, especially for patients in an immunosuppressed condition, as there is no specific medicine available for NTM, unlike M. tuberculosis. In hematopoietic stem cell or other solid organ recipients, the most common site of infection is the lung, with M. avium complex (MAC), the most commonly noted causative pathogen, followed by M. kansasii [14, 15]. Other studies have suggested that NTM infection rates of incidence in lung transplant recipients range from 1.5–22.4% (Table 2) [3, 4, 5, 6, 7, 8, 9, 10, 11]. In those reports, MAC was most common, followed by MABSC, while M. kansasii was not a major concern. However, there are also reports of rare types of NTM (Table 3), though the causative pathogens vary depending on region. In those cases, the most common infection site is a lung, followed by skin and soft tissue caused by rapid growers, such as MABSC or M. gordonae.
Table 2

Previous reports of NTM lung infection after lung transplant

Table 3

Pathogens classified by onset time

 

Early

Late

Very late

(n = 43)

(n = 35)

(n = 16)

MACa

4

13

5

MABSCb

11

10

9

M.gordonae

1

0

1

M.chelonae

1

0

0

M.siminae

0

1

0

M.kansasii

0

1

0

M.fortuitum

0

3

0

M.asiaticum

0

0

1

Not reported

26

7

0

aMAC mycobacterium avium complex

bMABSC Mycobacterium abscessus complex

We reviewed previous reports and classified those cases based on onset time after transplantation, with early onset considered to occur within 180 days, late onset from 180 days until 3 years, and very late onset after 3 years. There were 212 cases in which onset time was described (early onset, n = 43; late onset, n = 35; very late onset, n = 16) (Table 2), including 61 with both types of pathogens and onset time details (Table 3). MAC and MABSC were common organisms regardless of time of onset. In cases of early onset, the origin of NTM was newly acquired in some and prior to transplantation or donor-derived in others. On the other hand, patients in the very late onset group acquired a new infection under an immunosuppressed condition. All 16 cases had respiratory symptoms due to NTM pulmonary disease (Table 4). The average time from transplantation to onset was 6.1 years, and prognosis in most was good (Table 4). The direct cause of the three mortalities was not NTM, but rather bronchiolitis obliterans syndrome (BOS) in one [3], and either aspergillus or pneumonia infection in two [6].
Table 4

Details of very late onset reported cases

0

References

Age

Sex

Reason fot LuTx

LuTx

Time to onset

Symptoms

Chest X-ray findings

Culture

Pathogen

Drug for treatment

Outcome

1

1999

Malouf [3]

55

F

PAH

HL

8.9 years

Cough, sputum, dyspnea, fever

Normal

Sputum

MABSC

Ri + C + Ci

Alive

2

  

38

M

CHD

HL

4.3 years

Cough, sputum, dyspnea, fever

Bilateral apical infiltrate

BAL

M.avium

R + E + C + Ci

Alive

3

  

45

F

Empysema

SL

3.6 years

Cough, sputum, dyspnea, fever

Basal infiltrates

BAL

MAC

Ri + C + Ci

Alive

4

  

32

M

AATD

SL

3.6 years

Cough, dyspnea, fever

Apical and mid-zone infiltrates

Sputum

MAC

Ri + C + Ci

Dead

5

  

54

M

Empysema

SL

3.7 years

Cough, sputum, dyspnea, fever

Consolidation in midzone

BAL

M.avium

No treatment

Alive

6

  

48

M

AATD

SL

3.3 years

Cough, sputum, dyspnea, fever

Infiltrate in transpranted lung

Pleural fliud

M.asiaticum

R + E + P

Alive

7

2002

Fairhurst [5]

55

F

PAH

HL

9.0 years

Cough, sputum, dyspnea, fever

BAL

MABSC

Ri + C + Ci

Alive

8

2006

Chernenko [6]

40

F

Eisenmenger

HL

9.1 years

Fever, chills

Sputum

MABSC

R + C + Ci

Dead

9

  

48

M

COPD

SL

8.4 years

Fever, chills

BAL + sputum

MABSC

R + E + C

Dead

10

  

53

M

COPD

BL

8.5 years

Sputum

Normal

BAL + sputum

MABSC

R + E + Ci

Alive

11

  

39

M

CF

BL

9.3 years

Sputum

Nodules

Sputum

MABSC

Ri + C + Ci + E

Alive

12

  

42

F

LAM

BL

4.1 years

Sputum

Nodules

Sputum

MABSC

AMK + AZ + cefoxitin+Ci

Alive

13

2012

Knoll [8]

28

F

CF

BL

3.2 years

BAL

M.avium

Alive

14

2018

Our study

10

M

PAH

LDLT

6.3 years

None

Apical infiltrates

BAL

M.godnae

no treatment

Alive

15

  

35

F

BE

LDLT

6.8 years

Fever, sputum

Basal infiltrates

BAL

MABSC

TAZ/PIPC+AZM

Alive

16

  

41

F

LAM

SL

4.8 years

Sputum

Basal infiltrates

Sputum

MABSC

AZM + IPM + AMK

Alive

AATD α 1-antitrypsin deficiency, AMK amikacin, AZM azithromycin, BAL bronchoalveolar lavage, BE bronchiectasis, BL bilatetal lung, C Clarithromycin, CF cystic fibrosis, CHD congenital heart disease, Ci ciprofloxacin, COPD chronic obstructive pulmonary disease, E Ethambutol, HL heart-lung, IPM imipenem, LAM lymphangioleiomyomatosis, LDLT living donor lung transplantation, P Pyridoxal Phosphate Hydrate, PAH pulmonary arterial hypertension, R rifampicin, Ri Rifabutin, SL single lung, TAZ/PIPC Tazobactam / Piperacillin

Chronic rejection is known to be associated with NTM infection [3], and bronchiolitis obliterans syndrome is likely to occur in patients with NTM detected [7, 9]. Most of the patients in our cohort had respiratory symptoms, such as cough, sputum, and fever, with imaging showing consolidation suggesting pneumonia, and were diagnosed based on sputum culture or BAL results. Aggravation of a pulmonary infection in cases affected by immunosuppression will occur if an inappropriate antibiotic medicine is administered. Sputum obtained by expectoration may not be representative of sputum from deeper parts; thus, it is useful to first perform BAL to detect pathogens with the possibility of a combined infection of acid-fast bacteria or fungus kept in mind. The percentage of patients with MABSC was high (56.3%), which included therapy resistant cases ending in death from respiratory failure, though that rate may be falsely high because of selection bias. It is important for physicians to be aware that the risk of NTM infection continues for a long period after transplantation, as that was previously reported to occur in a patient after 9 years [6], and such occurrence may be via the same mechanism seen in the general population. NTM can destroy the lung structure, leading to decreased respiratory function [12]. Thus, care must be taken regarding reduction of immunosuppressive agents because respiratory function can worsen if rejection occurs. In most reports, overall survival after lung transplantation was not influenced by NTM infection [8, 9], though George et al. found that the survival rate of pulmonary NTM disease was lower than that of subclinical infection cases [10]. On the other hand, another investigation found that it was similar between cases of single lung transplantation and those with BOS [7].

Selection of the optimum antibiotic medication for treatment is crucial, though dependent on the sensitivity of each pathogen according to the ATS guidelines and must also be adjusted in accordance with the prescribed immunosuppressive agents. On the other hand, that is dependent on individual patient state regarding which agents can be reduced. PSL was decreased in two of our cases and only case 1 showed improvement with treatment. RFP, administered for MAC, attenuates the effect of ciclosporin; thus, it is necessary to increase its dose by 3–5 times above the standard when administered. The present case 4 was given an approximately threefold greater dose of ciclosporin while receiving the standard RFP dosage. Ciclosporin must be adjusted by monitoring its concentration in blood, as that varies in each patient from a variety of factors.

Conclusions

An NTM infection and pulmonary disease can occur several years following lung transplantation. It is necessary to consider the best treatment for affected patients based on the pathogens involved, individual status, and disease severity, including which antibiotic medicine should be selected and which immunosuppressive agent can be decreased.

Notes

Acknowledgements

Not applicable.

Funding

This study was not funded.

Availability of data and materials

There were no available repositories.

Authors’ contributions

NO described and designed the article. YS supervised the edition of the manuscript. Other remaining co-authors collected the data and discussed the content of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Ethical Review Board for Clinical Studies at Osaka University (control number 10026–3).

Consent for publication

Informed consent was obtained from the patient for the publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.CrossRefGoogle Scholar
  2. 2.
    Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576–83.CrossRefGoogle Scholar
  3. 3.
    Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med. 1999;160:1611–6.CrossRefGoogle Scholar
  4. 4.
    Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest. 1999;115:741–5.CrossRefGoogle Scholar
  5. 5.
    Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant. 2002;21:391–4.CrossRefGoogle Scholar
  6. 6.
    Chernenko SM, Humar A, Hutcheon M, Chow CW, Chaparro C, Keshavjee S, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant. 2006;25:1447–55.CrossRefGoogle Scholar
  7. 7.
    Huang HC, Weigt SS, Derhovanessian A, Palchevskiy V, Ardehali A, Saggar R, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant. 2011;30:790–8.CrossRefGoogle Scholar
  8. 8.
    Knoll BM, Kappagoda S, Gill RR, Goldberg HJ, Boyle K, Baden LR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis. 2012;14:452–60.CrossRefGoogle Scholar
  9. 9.
    Shah SK, McAnally KJ, Seoane L, Lombard GA, LaPlace SG, Lick S, et al. Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation. Transpl Infect Dis. 2016;18:585–91.CrossRefGoogle Scholar
  10. 10.
    George IA, Santos CA, Olsen MA, Bailey TC. Epidemiology and outcomes of nontuberculous mycobacterial infections in solid organ transplant recipients at a Midwestern center. Transplantation. 2016;100:1073–8.CrossRefGoogle Scholar
  11. 11.
    Tachibana K, Okada Y, Matsuda Y, Miyoshi K, Oto T, Chen-Yoshikawa TF, et al. Nontuberculous mycobacterial and Aspergillus infections among cadaveric lung transplant recipients in Japan. Respir Investig. 2018;56:243–8.CrossRefGoogle Scholar
  12. 12.
    Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354:751–7.CrossRefGoogle Scholar
  13. 13.
    Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71:88–90.CrossRefGoogle Scholar
  14. 14.
    Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994;19:263–73.CrossRefGoogle Scholar
  15. 15.
    Queipo JA, Broseta E, Santos M, Sánchez-Plumed J, Budía A, Jiménez-Cruz F. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003;9:518–25.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of General Thoracic SurgeryOsaka University Graduate School of MedicineSuita-shiJapan

Personalised recommendations